Abstract
Prostate cancer is the most common cancer for man with a high mortality rate due to a lack of non-invasive accurate and sensitive molecular diagnostic methods. The molecular imaging of cancer biomarkers using MRI with its spatial and temporal resolution, however, is largely limited by the lack of contrast agents with high sensitivity, targeting specificity and deep tumor penetration. In this review, we will first overview the current stage of prostate cancer diagnosis and then review prostate cancer biomarkers and related imaging techniques. Since biomarker targeting moieties are essential for molecular imaging, we will use prostate-specific membrane antigen (PSMA) as an example to discuss different methods to characterize the interaction between biomarker and targeting moieties. At the end, we will review current progress of the development of targeted protein-based MRI contrast agents (ProCAs) for prostate cancer biomarkers with improved relaxivity and targeting capability.
Keywords: Molecular imaging, protein-based MRI contrast agents, GRPR, PSMA, biomarkers.
Current Protein & Peptide Science
Title:Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Volume: 17 Issue: 6
Author(s): Fan Pu, Shenghui Xue, Jingjuan Qiao, Anvi Patel and Jenny J. Yang
Affiliation:
Keywords: Molecular imaging, protein-based MRI contrast agents, GRPR, PSMA, biomarkers.
Abstract: Prostate cancer is the most common cancer for man with a high mortality rate due to a lack of non-invasive accurate and sensitive molecular diagnostic methods. The molecular imaging of cancer biomarkers using MRI with its spatial and temporal resolution, however, is largely limited by the lack of contrast agents with high sensitivity, targeting specificity and deep tumor penetration. In this review, we will first overview the current stage of prostate cancer diagnosis and then review prostate cancer biomarkers and related imaging techniques. Since biomarker targeting moieties are essential for molecular imaging, we will use prostate-specific membrane antigen (PSMA) as an example to discuss different methods to characterize the interaction between biomarker and targeting moieties. At the end, we will review current progress of the development of targeted protein-based MRI contrast agents (ProCAs) for prostate cancer biomarkers with improved relaxivity and targeting capability.
Export Options
About this article
Cite this article as:
Pu Fan, Xue Shenghui, Qiao Jingjuan, Patel Anvi and Yang J. Jenny, Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents, Current Protein & Peptide Science 2016; 17 (6) . https://dx.doi.org/10.2174/1389203717666160101123725
DOI https://dx.doi.org/10.2174/1389203717666160101123725 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Current Drug Abuse Reviews Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Current Cancer Drug Targets Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers
Current Pharmaceutical Biotechnology Recent Developments in Receptor-Selective Retinoids
Current Pharmaceutical Design The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Inhibition of Early Biochemical Defects in Prodromal Huntington’s disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients
Current Aging Science Smart Polymer Based Delivery Systems for Peptides and Proteins
Recent Patents on Drug Delivery & Formulation Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Synthesis, Biochemical Evaluation and Rationalisation of a Series of (3-O-Sulfonate) Derivatives of Estrone (E1) as Probes of the Active Site of Type 3 of the 17β-Hydroxysteroid Dehydrogenase (17β-HSD) Family of Enzymes
Letters in Drug Design & Discovery Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine